Dicerna Announces Expiration Of Hart-Scott-Rodino Act Waiting Period For Novo Nordisk Tender Offer To Acquire Dicerna
Dec 25, 2021•almost 4 years ago
Acquiring Company
Diceros Therapeutics
Acquired Company
Diceros Therapeutics
NewtonNewtonBiotechnologyBiotechnologyDescription
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed